| Identification | Back Directory | [Name]
4-Pyridinecarboxamide, 2-[[[(2R)-1-[1-[(4-chloro-3-methylphenyl)methyl]-4-piperidinyl]-5-oxo-2-pyrrolidinyl]carbonyl]amino]-N,N,6-trimethyl-, hydrochloride (1:2) | [CAS]
1372127-19-9 | [Synonyms]
4-Pyridinecarboxamide, 2-[[[(2R)-1-[1-[(4-chloro-3-methylphenyl)methyl]-4-piperidinyl]-5-oxo-2-pyrrolidinyl]carbonyl]amino]-N,N,6-trimethyl-, hydrochloride (1:2) | [Molecular Formula]
C27H35Cl2N5O3 | [MOL File]
1372127-19-9.mol | [Molecular Weight]
548.51 |
| Hazard Information | Back Directory | [Uses]
ALK4290 dihydrochloride (AKST4290 dihydrochlorid) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a Ki of 3.2 nM for hCCR3[1]. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism[2][3]. | [References]
[1] Samanta A, te, al. Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. Asia Pac J Ophthalmol (Phila). May-Jun 2020; 9(3):250-259. DOI:10.1097/APO.0000000000000291
[2] NIVENS MC, et, al. Use of ccr3-inhibitors. US20130261153A1. |
|
|